Compare MDV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | CRBU |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Transportation Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.5M | 167.6M |
| IPO Year | N/A | 2021 |
| Metric | MDV | CRBU |
|---|---|---|
| Price | $18.00 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $18.00 | $10.75 |
| AVG Volume (30 Days) | 55.5K | ★ 1.9M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | $8.56 | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.80 | $1.22 |
| 52 Week High | $18.83 | $3.53 |
| Indicator | MDV | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 36.78 |
| Support Level | $17.60 | $1.39 |
| Resistance Level | $18.75 | $1.73 |
| Average True Range (ATR) | 0.37 | 0.14 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 30.33 | 13.01 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in, and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from the company's consolidated real estate properties.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.